3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
21
Unknown
8
Terminated
6
Withdrawn
2
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
3
Melanoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Obesity
2
Infertility
2
Glioblastoma
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
TP53 Y220C Mutation
1
Sarcoma, Ewing
1
Sarcoma
1
Prostate Cancer Recurrent
1
Progression-Free Survival
1
Preleukemia
1
Posterior Fossa Ependymal Tumor
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Metabolic Diseases
1
Medulloblastoma
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Acute
1
Insulin Resistance
1
Hyperandrogenism
1
Interventions
Fulvestrant
58
Trastuzumab
49
Capecitabine
48
Letrozole
45
pembrolizumab
41
Carboplatin
41
Paclitaxel
39
Cyclophosphamide
38
ribociclib
37
pertuzumab
36
abemaciclib
36
Blood Specimen Collection
31
Specimen Handling
28
trastuzumab deruxtecan
27
Docetaxel
27
Surveys and Questionnaires
26
Anastrozole
25
exemestane
24
Tamoxifen
24
palbociclib
21
130-nm albumin-bound paclitaxel
21
Magnetic Resonance Spectroscopy
20
Biopsy
19
sacituzumab govitecan
18
eribulin
18
Radiotherapy
18
Gemcitabine
18
olaparib
17
Injections
17
Epirubicin
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Breast Neoplasms
×
Metformin
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled